Febrile Neutropenia Done by Asma Essa AlTameem
Definition
Febrile neutropenia occurs when a patient has a fever and a
significant reduction in a type of white blood cells, known as
neutrophils, which are needed to fight infections.
Neutropenia is defined as an absolute neutrophil count (ANC) of less than
500/µL, or less than 1000/µL with an anticipated decline to less than 500/µL in
the next 48-hour period.
Neutropenic Fever is a single oral temperature of 38.3º C (101º F) or a
temperature of greater than 38.0º C ( 100.4º F) sustained for more than 1 hour in
a patient with neutropenia
Predisposing Factors
1. Malignancy : Type , Stage , Advanced or Refractory , Obstructive
2. Leukemia and lymphomas, which are malignancies of the hematopoietic system, are associated with a particularly high
incidence of neutropenia
3. Surgical Risk
4. Chemotherapy
5. Irradiation
6. Grade of Neutropenia
7. Mucosal breakdown : Mucositis
8. Patients with cancer typically have other potential entry points for infection, including IV catheters, sites of surgical
manipulation , and areas of abnormal anatomic architecture created by the tumors themselves
9. Medications : Corticosteroid Use
Microbiology Mainly Gram-Positive organisms (~70%)
Coagulase-negative staphylococci
Staphylococcus aureus
Streptococcal viridans
Enterococci
Gram-Negative organisms
Coliforms (E.coli, Klebsiella, Enterobacter)
Pseudomonas aeruginosa
Yeast
Candida
Aspergillus
Viruses
Herpes simplex (HSV)
Influenza, paranifluenza
CMV
Microbiology
Neutropenic patients are vulnerable to numerous infectious organisms
Gut (eg, Escherichia coli, Enterobacter, anaerobes)
Skin (eg, Staphylococcus, Streptococcus)
Respiratory Tract (eg, Streptococcus pneumoniae, Klebsiella, Corynebacterium, Pseudomonas)
Other areas that are susceptible to opportunistic colonization (eg, by Clostridium difficile,
Mycobacterium, Candida, Aspergillus).
Diagnosis
History
Physical Examination
Lab Assessments
Diagnostic Imaging
Medical History
Chemotherapy regimen & last dose given
Prophylactic antibiotic
Steroid use
Major comorbidities
Recent surgical procedures
Recent infections or positive cultures
Previous antibiotic-resistant organisms or bacteraemia
Recent exposures
Presence of vascular devices
Allergies
Physical Examination Site Signs
Skin No skin lesions associated with central venous access device
Oro-pharyngeal tract No mucositis
Gastrointestinal tract No nausea , vomiting , or dysphagia
Respiratory tract Presence Mild cough
Genitourinary tract Presence of yeast infection
Central nervous system No CNV symptoms
Lab Assessments
CBC
RFT : electrolytes , Cr , BUN
LFT
Coagulation screen
C- reactive protein
Urinalysis
Stool microscopy for C.difficle if patient has diarrhea
Lab Assessments
Blood cultures
1 catheter + 1 peripheral
2 catheter
2 peripheral
Urine culture
if symptomatic
urinary catheter
or abnormal urinalysis
Stool culture , if patient has diarrhea
Skin lesion swab , biopsy and culture
Sputum culture , if patient has productive cough
Diagnostic Imaging
Chest X rays
Brain CT , MRI ; if patient has CNS symptoms
Abdominal Ct , US ; if patient has abdominal pain
Risk Assessment
The Multinational Association for Supportive
Care in Cancer (MASCC) Risk Index
Low – Risk Patient
Less than 7 days ( duration of neutropenia )
ACN more than 100/µl
Outpatient status at the time of fever
Normal findings on chest x rays
No associated acute comorbidities
No hepatic or renal insufficiency
MASCC Risk Index score >21
Early evidence of bone marrow recovery
High– Risk Patient
More than 7 days ( duration of neutropenia )
Profound neutropenia , ACN less than 100/µl
Inpatient status at the time of fever
CrCl less than 30
MASCC Risk Index score <21
Significant medical comorbidities :
Hypotension
Pneumonia
New-onset abdominal pain
Neurologic changes
Treatment
IV Monotherapy
B-lactams
Cefepime
Imepinum
Meropenum
Tazobactum
IV Combination Therapy
Aminoglycoside + (meropenem, imipenem-cilastin or piperacillin-tazobactam)
Aminoglycoside + (cefepime or ceftazidime)
Ciprofloxacin + (meropenem, imipenem-cilastin or piperacillin-tazobactam)
Piperacillin-tazobactam
Broad spectrum gram(-), gram(+) & anaerobic coverage
Imipenem-cilastin – Meropenem
Broad spectrum gram(-), gram(+) & anaerobic and ESBL coverage
Meropenem is Preferred for meningitis/CNS infection
Ceftazidime
Poor gram(+) activity
Good CSF penetration
Aminoglycosides
Gram(-) coverage, synergy with beta-lactams against S.aureus and Enterococcus
Side effects :Nephrotoxicity, ototoxicity
Ciprofloxacin
Gram(-) and atypical bacterial coverage
less gram(+) activity than other options
Avoid in patients recently treated with quinolone prophylaxis
Vancomycin
Vancomycin not routinely recommended for empiric therapy
Specific indications:
Clinically suspected serious catheter-related infection
Known colonization with MRSA or pcn/ceph-resistant pneumococci
Gram-positive bacteremia pending further C&S
Hypotension or other cardiovascular impairment
Soft-tissue infection
Risk factors for viridans strep bacteremia (severe mucositis )
Reassess Vancomycin after 24-48 hours
Fungal Infection
Antifungal Considered if the patient is febrile after 3-5 days and remains
neutropenic
Liposomal Amphotericin B = aspergillosis, candida
Fluconazole = Candida species
Voriconazole = fluconazole-resistant Candida, amphotericin-B-resistant
Aspergillus
Caspofungin = Candida, Aspergillus , and Histoplasma
It is active against fluconazole-resistant and fluconazole-susceptible strains of Candida
albicans.
Antiviral Acyclovir , Valacyclovir:
HSV or VZV treatment
Ganciclovir:
CMV treatment
Foscarnet:
Acyclovir-resistant HSV , CMV treatment
Oseltamivir:
Influenza - reduced doses required in renal impairment
When to add antiviral drugs?
Oral lesions: HSV
Esophageal lesions: HSV, CMV
Skin lesions: VZV
Pneumonia: Influenza
CNS symptoms: HSV
Nursing Management
Nursing Management
Monitor pt’s VS every 2 hrs and look for clinical symptoms ( lesion , cough )
Administer medication as ordere
Maintain aseptic technique
Provide antibacterial diet
Daily F/U with lab results (CBC , NE ,RFT)
Educate the pt